ライフサイエンスコーパス: ischaemic stroke

1 Hg; p=0.0007 for difference from decrease in ischaemic stroke).

2 fe and well tolerated in patients with acute ischaemic stroke.

3 ppocampal CA1 region is highly vulnerable to ischaemic stroke.

4 on of tissue plasminogen activator (tPA) for ischaemic stroke.

5 icity in the subacute to chronic phase after ischaemic stroke.

6 he only approved medical treatment for acute ischaemic stroke.

7 prospective cohort of 12 patients with acute ischaemic stroke.

8 (AD) increases dramatically in patients with ischaemic stroke.

9 non-fatal, and for haemorrhagic rather than ischaemic stroke.

10 We identified 96 cases of arterial ischaemic stroke.

11 3Kdelta as a potential therapeutic target in ischaemic stroke.

12 orrhage (regression p<0.0001) but not before ischaemic stroke.

13 safety and efficacy in a clinical trial for ischaemic stroke.

14 and powerful therapeutic strategies in acute ischaemic stroke.

15 the frequency of TNAs before vertebrobasilar ischaemic stroke.

16 non-significant increase in the incidence of ischaemic stroke.

17 novel therapeutic target in the aftermath of ischaemic stroke.

18 (MCI) or dementia after lacunar or cortical ischaemic stroke.

19 ntly increase alteplase use in patients with ischaemic stroke.

20 ingle largest non-modifiable risk factor for ischaemic stroke.

21 hted imaging (DWI) typically indicates acute ischaemic stroke.

22 outcome and function in patients with acute ischaemic stroke.

23 cation of intravenous thrombolysis for acute ischaemic stroke.

24 ctiveness of cell transplantation therapy in ischaemic stroke.

25 ice for endovascular recanalisation in acute ischaemic stroke.

26 n the diagnostic evaluation of patients with ischaemic stroke.

27 ctiveness of cell transplantation therapy in ischaemic stroke.

28 enetics of both monogenic and multifactorial ischaemic stroke.

29 hese have identified novel associations with ischaemic stroke.

30 als with a high susceptibility of developing ischaemic stroke.

31 nd absence of haemorrhage or other causes of ischaemic stroke.

32 on is implicated in several aspects of acute ischaemic stroke.

33 under investigation as a treatment for acute ischaemic stroke.

34 locus conferring a large effect on risk for ischaemic stroke.

35 acy and safety of thrombolytic treatment for ischaemic stroke.

36 nditions induced by hypoxia, starvation, and ischaemic stroke.

37 , 3, 7 and 14 days (peaking at 7 days) after ischaemic stroke.

38 ting the best therapy in patients with acute ischaemic stroke.

39 l processes underlying these two subtypes of ischaemic stroke.

40 rosclerosis and a strong predictor of future ischaemic stroke.

41 cule alpha4 integrin, in patients with acute ischaemic stroke.

42 the major venous imaging-based biomarkers in ischaemic stroke.

43 tly correlates with stroke outcomes in acute ischaemic stroke.

44 l patterns associated with headache in acute ischaemic stroke.

45 ated to the development of headache in acute ischaemic stroke.

46 on motor recovery in patients after an acute ischaemic stroke.

47 or untreated control) in patients with acute ischaemic stroke.

48 rd care or standard care alone within 6 h of ischaemic stroke.

49 outcome when delivered within 4.5 h of acute ischaemic stroke.

50 f pH-weighted imaging in patients with acute ischaemic stroke.

51 are now thought to comprise about 25% of all ischaemic strokes.

52 ogen activator) alone for moderate or severe ischaemic strokes.

53 se is one of the major preventable causes of ischaemic strokes.

54 p=0.005), particularly of disabling or fatal ischaemic stroke (0.64, 0.49-0.84, p=0.0010).

55 jor coronary event (2.44, 95% CI 2.18-2.73), ischaemic stroke (1.68, 95% CI 1.60-1.77), and intracere

56 sease (adjusted HR 2.98 [95% CI 2.76-3.22]), ischaemic stroke (1.72 [1.52-1.95]), stable angina (1.62

57 ecific hazard ratio 2.98, 95% CI 2.76-3.22), ischaemic stroke (1.72, 1.52-1.95), stable angina (1.62,

58 , 0.43-1.00; p=0.05), but significantly more ischaemic strokes (1.28, 1.02-1.60; p=0.045).

59 e; 1.08 (0.97-1.20) and 1.14 (1.02-1.27) for ischaemic stroke; 1.16 (1.09-1.24) and 1.13 (1.05-1.22)

60 coronary heart disease; 1.32 (1.18-1.49) for ischaemic stroke; 1.34 (1.18-1.52) for vascular mortalit

61 coronary heart disease; 2.27 (1.95-2.65) for ischaemic stroke; 1.56 (1.19-2.05) for haemorrhagic stro

62 s; 1.44 (1.32-1.57) and 1.27 (1.15-1.40) for ischaemic stroke; 1.71 (1.53-1.91) and 1.55 (1.37-1.76)

63 This gain chiefly involved carotid territory ischaemic strokes (2.7% vs 9.5%; gain 6.8% [4.8-8.8], p<

64 In animal models of ischaemic stroke, 25% albumin reduced brain infarction a

65 Of the 597 disabling/fatal incident ischaemic strokes, 369 occurred at age >/=80 years, of w

66 the PAR for all stroke worldwide (91.5% for ischaemic stroke, 87.1% for intracerebral haemorrhage),

67 Acute ischaemic stroke accounts for 6.5 million deaths per yea

68 Some further reduction in risk of ischaemic stroke accrued for aspirin only versus control

69 Risks of recurrent ICH and ischaemic stroke after ICH appear similar after ICH, pro

70 ies reporting the risks of recurrent ICH and ischaemic stroke after ICH found no significant differen

71 le-blind, phase 2 study, patients with acute ischaemic stroke (aged 18-85 years) from 30 US and Europ

72 11 stroke survivors with a first-ever TIA or ischaemic stroke, aged 18-50 years.

73 Ninety-six children with an arterial ischaemic stroke (AIS) and 43 with a haemorrhagic stroke

74 Arterial ischaemic stroke (AIS) is an important cause of acquired

75 For childhood-onset arterial ischaemic stroke (AIS), treatment trials are lacking and

76 BB) isoform increased in patients with acute ischaemic stroke (AIS).

77 at patients as early as possible after acute ischaemic stroke, although some patients might benefit u

78 died 27 patients with acute right hemisphere ischaemic stroke and 24 neurologically intact inpatients

79 from 32 countries (13 447 cases [10 388 with ischaemic stroke and 3059 intracerebral haemorrhage] and

80 orts with a total of 12 389 individuals with ischaemic stroke and 62 004 controls, all of European an

81 ults (aged 18-85 years) who had a first-ever ischaemic stroke and a motor deficit of the upper extrem

82 ged 18-83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Str

83 into the pathogenesis of childhood arterial ischaemic stroke and cerebral arteriopathy, provided by

84 f the effect of aspirin on risk of recurrent ischaemic stroke and how this differs by severity at bas

85 n is based on a balance between reduction in ischaemic stroke and increase in major bleeding.

86 The relation between acute ischaemic stroke and infection is complex.

87 ntral nervous system, particularly following ischaemic stroke and its aberrant activation is directly

88 a young transient ischaemic attack (TIA) or ischaemic stroke and its association with functional out

89 s through meta-analysis of GWAS datasets for ischaemic stroke and its subtypes.

90 acerbate blood-brain barrier breakdown after ischaemic stroke and lead to lethal haemorrhagic transfo

91 ional outcome when given to patients who had ischaemic stroke and major cerebral artery occlusion bey

92 protect against necrotic injuries, including ischaemic stroke and myocardial infarction.

93 ts from 77 hospitals in 17 countries who had ischaemic stroke and occlusion or high-grade stenosis in

94 High rates of recurrent ischaemic stroke and other cardiovascular events mandate

95 mitochondrial mechanisms in the aetiology of ischaemic stroke and provide a new means for the identif

96 d one ischaemic stroke) and two PCC related (ischaemic stroke and pulmonary embolism).

97 oke might differ between patients with major ischaemic stroke and those with primary intracerebral ha

98 ence of transient ischaemic attack (TIA) and ischaemic stroke and were compared with those of patient

99 002 and 31 June 2011 for space-occupying MCA ischaemic stroke and who underwent DHC.

100 st, a relative increase in the proportion of ischaemic strokes and a decline in haemorrhagic strokes.

101 rtant trigger that precedes up to a third of ischaemic strokes and can bring about stroke through a r

102 xpansion, one anaphylactic reaction, and one ischaemic stroke) and two PCC related (ischaemic stroke

103 ed to oxygen glucose deprivation (a model of ischaemic stroke), and in hippocampal pyramidal neuron c

104 vs 101 [47%] of 213 patients with recurrent ischaemic stroke), and outnumbered disabling or fatal in

105 stroke but 44% (95% CI 34-54) with recurrent ischaemic stroke, and 52% (95% CI 47-56) with first-ever

106 hy adults, 34% (95% CI 31-36) in people with ischaemic stroke, and 60% (95% CI 57-64) in people with

107 nt of all-cause stroke or systemic embolism, ischaemic stroke, and all-cause mortality.

108 te stroke (ischaemic or haemorrhagic), acute ischaemic stroke, and chronic haemorrhage more frequentl

109 ccident and emergency departments with acute ischaemic stroke, and focuses on thrombolysis.

110 only the first few days after TIA and minor ischaemic stroke, and observational studies show substan

111 It is well protected against ischaemic stroke, and so there is relatively little neur

112 s reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularis

113 erting a moderate to large effect on risk of ischaemic stroke, and to generate publicly available gen

114 rimary intracerebral haemorrhage and lacunar ischaemic stroke are acute manifestations of progressive

115 t because new treatment strategies for acute ischaemic stroke are being investigated, including those

116 combined with reperfusion therapies in acute ischaemic stroke are ongoing.

117 Cryptogenic (of unknown cause) ischaemic strokes are now thought to comprise about 25%

118 rd of transient ischaemic attacks (TIAs) and ischaemic strokes are of undetermined cause (ie, cryptog

119 Arterial ischaemic stroke around the time of birth is recognised

120 Inflammation is implicated in ischaemic stroke as a general cardiovascular risk factor

121 ew oral anticoagulants for the prevention of ischaemic stroke, as well as bleeding risk assessment, m

122 on-fatal myocardial infarction, or non-fatal ischaemic stroke) associated with cumulative burden of r

123 The reduction in risk of recurrent ischaemic stroke at 14 days was most evident in patients

124 re was no difference in the risk of arterial ischaemic stroke between sexes (crude incidence 1.60 per

125 In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium

126 affected 23% (95% CI 18-29) with first-ever ischaemic stroke but 44% (95% CI 34-54) with recurrent i

127 lteplase is effective for treatment of acute ischaemic stroke but debate continues about its use afte

128 c factors have a role in the pathogenesis of ischaemic stroke, but the main genes involved have yet t

129 Headache is a common symptom in acute ischaemic stroke, but the underlying mechanisms are inco

130 fractionated heparin is recommended in acute ischaemic stroke, but which regimen provides optimum tre

131 Aspirin reduced the 6 week risk of recurrent ischaemic stroke by about 60% (84 of 8452 participants i

132 0.32-0.55, p<0.0001) and disabling or fatal ischaemic stroke by about 70% (36 of 8452 vs 110 of 7326

133 Accurate diagnosis in suspected ischaemic stroke can be difficult.

134 three studies, an extension cohort of 12 577 ischaemic stroke cases and 25 643 controls from NINDS-Si

135 INDS-SiGN, and a validation cohort of 10 307 ischaemic stroke cases and 29 326 controls from METASTRO

136 standard medical care in patients with acute ischaemic stroke caused by occlusion of arteries of the

137 In these trials, patients with acute ischaemic stroke caused by occlusion of the proximal ant

138 my is of benefit to most patients with acute ischaemic stroke caused by occlusion of the proximal ant

139 We meta-analysed data from 15 ischaemic stroke cohorts with a total of 12 389 individu

140 Treatments for acute ischaemic stroke continue to evolve.

141 'cryptogenic' stroke accounts for 30-40% of ischaemic strokes despite extensive diagnostic evaluatio

142 t, to maximise success of genetic studies in ischaemic stroke, detailed stroke subtyping is required.

143 009, there were an estimated 4 909 519 acute ischaemic stroke discharges.

144 ety of endovascular treatment (EVT) in acute ischaemic stroke due to cervical and/or cerebral arteria

145 vide timely treatment to patients with acute ischaemic stroke due to large vessel occlusion.

146 uals with and without diabetes) and incident ischaemic stroke during follow-up using Cox proportional

147 The emphasis of treatments for acute ischaemic stroke during the past two decades has been on

148 Early after acute ischaemic stroke, elevation of brain temperature might a

149 evaluation study, adults with supratentorial ischaemic stroke eligible for intravenous thrombolysis w

150 results suggest that for patients with acute ischaemic stroke, enoxaparin is preferable to unfraction

151 Of 687 children with acute arterial ischaemic stroke enrolled in the IPSS, 15 (2%) received

152 rial fibrillation is found in a third of all ischaemic strokes, even more after post-stroke atrial fi

153 Mortality rates for ischaemic stroke fell by 14% (9-19), DALYs lost by 17% (

154 The risk of ipsilateral ischaemic stroke for patients on medical treatment, the

155 intravenous alteplase for treatment of acute ischaemic stroke for which data were available.

156 hire, UK, among patients with a first TIA or ischaemic stroke from April 1, 2002, to March 31, 2014,

157 eview we summarise the state of knowledge in ischaemic stroke genetics particularly in the context of

158 mes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortali

159 ON THIS ARTICLE: About 20% of patients with ischaemic stroke have a preceding transient ischaemic at

160 pulation-based studies of childhood arterial ischaemic stroke have been undertaken.

161 tive trials of endovascular thrombectomy for ischaemic stroke have provided level 1 evidence for impr

162 mechanisms implicated in childhood arterial ischaemic stroke have received little attention, but an

163 ical benefit of 25% albumin in patients with ischaemic stroke; however, they should not discourage fu

164 association studies (GWAS) have been done in ischaemic stroke, identifying a few loci associated with

165 ndomised trials testing treatments for acute ischaemic stroke, imaging markers of tissue reperfusion

166 t tissue plasminogen activator (rt-PA) after ischaemic stroke improves outcome.

167 MRI detected acute ischaemic stroke in 164 of 356 patients (46%; 95% CI 41-

168 hin 3 h of symptom onset, MRI detected acute ischaemic stroke in 41 of 90 patients (46%; 35-56%); CT

169 and clinical features of childhood arterial ischaemic stroke in a population-based cohort.

170 atomical and functional recovery after focal ischaemic stroke in an elderly nervous system.

171 ce from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and met

172 (OAC) remains the mainstay for prevention of ischaemic stroke in atrial fibrillation.

173 Acute ischaemic stroke in brain areas contributing to male sex

174 s of the use of alteplase for acute arterial ischaemic stroke in children enrolled in an internationa

175 , but not sex, affected the risk of arterial ischaemic stroke in children.

176 nfirmed benefit on major coronary events and ischaemic stroke in many diabetic patient subgroups, inc

177 aemic events during the 90 days preceding an ischaemic stroke in patients ascertained within a prospe

178 aemic events during the 90 days preceding an ischaemic stroke in patients ascertained within a prospe

179 sk of symptomatic ICH after thrombolysis for ischaemic stroke in patients with CMBs.

180 outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is

181 patients with transient ischaemic attack or ischaemic stroke in the acute phase and the long term, a

182 higher proportion of patients had recurrent ischaemic stroke in the intra-arterial treatment plus us

183 culation transient ischaemic attack or minor ischaemic stroke in the Oxford Vascular Study and relate

184 oke or death within 30 days after enrolment, ischaemic stroke in the territory of the qualifying arte

185 Complications after ischaemic stroke, including both neurological and medica

186 bumin given within 5 h of the onset of acute ischaemic stroke increased the proportion of patients wi

187 Ischaemic stroke induces endogenous repair processes tha

188 Ischaemic stroke is a heterogeneous disease caused by di

189 nd show that endovascular treatment of acute ischaemic stroke is a therapeutic option for patients wh

190 Arterial ischaemic stroke is an important cause of acquired brain

191 en activator (rtPA) on functional outcome in ischaemic stroke is clear, but there are some treated pa

192 Recovery from ischaemic stroke is dependent on survival of neurones, p

193 Heritability of ischaemic stroke is greater in women than in men, with a

194 te-phase systolic blood pressure after major ischaemic stroke is much closer to the accustomed long-t

195 Ischaemic stroke is one of the leading causes of death a

196 Ischaemic stroke is partly heritable.

197 proach to intravenous thrombolysis for acute ischaemic stroke is pivotal, it is imperative to examine

198 e use of CMR in the diagnostic evaluation of ischaemic stroke is sparse.

199 Ischaemic stroke is the leading cause of severe long-ter

200 ffect of alteplase on patient survival after ischaemic stroke is the subject of debate.

201 Currently, the only approved treatment for ischaemic stroke is tissue plasminogen activator, a clot

202 l links between Alzheimer's disease (AD) and Ischaemic Stroke (IS).

203 ke system, REACH (remote evaluation of acute ischaemic stroke), is a low-cost, web-based system that

204 nance spectroscopic imaging across the acute ischaemic stroke lesion and normal brain as determined o

205 st cancer, colorectal cancer, endometriosis, ischaemic stroke, leukemia, lymphoma and osteoarthritis.

206 e cohort studies, included all stroke or all ischaemic stroke, measured dementia by standard criteria

207 ls and are implicated in perception of pain, ischaemic stroke, mechanosensation, learning and memory.

208 Patients with acute ischaemic stroke (n = 100) were assessed by brain MRI at

209 oach to a cohort of samples with and without ischaemic stroke (n=278 and 275, respectively), and did

210 are records in all patients with acute major ischaemic stroke (National Institutes of Health Stroke S

211 years with radiologically confirmed arterial ischaemic stroke occurring over a 1-year period (July 1,

212 tion of 19% (95% CI 15-24; p<0.0001), and in ischaemic stroke of 16% (95% CI 5-26; p=0.005).

213 venous alteplase on long-term survival after ischaemic stroke of participants in the Third Internatio

214 on after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% re

215 l benefit of neurothrombectomy within 6 h of ischaemic stroke onset, which has initiated a new era of

216 om disorders of the cerebrovasculature, i.e. ischaemic stroke or haemorrhage.

217 6.15), lung cancer (RR 3.78, 2.78-5.14), and ischaemic stroke or ischaemic heart disease (combined RR

218 ong insulin-resistant patients with a recent ischaemic stroke or TIA, pioglitazone did not affect cog

219 n with cognitive impairment in patients with ischaemic stroke or TIA.

220 Stroke (IRIS) trial, patients with a recent ischaemic stroke or transient ischaemic attack (TIA) wer

221 ed-endpoint trial in adult participants with ischaemic stroke or transient ischaemic attack (TIA) wit

222 e relatives in female and male probands with ischaemic stroke or transient ischaemic attack in the po

223 , or death at 90 days in patients with acute ischaemic stroke or transient ischaemic attack when asso

224 r with a non-cardioembolic, non-severe acute ischaemic stroke, or high-risk transient ischaemic attac

225 nts with a first transient ischaemic attack, ischaemic stroke, or myocardial infarction treated with

226 cular disease, were followed up for incident ischaemic stroke over 8-10 years.

227 and cardiac causes were more associated with ischaemic stroke (p<0.0001).

228 s with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration).

229 Only a small percentage of acute ischaemic stroke patients meet criteria for rt-PA; there

230 In total, 5035 acute ischaemic stroke patients were enrolled.

231 We assessed functional outcome in ischaemic stroke patients with large vessel anterior cir

232 ly reduced soon after stroke onset (84 acute ischaemic stroke patients with or without intravenous tP

233 domised trials of endovascular treatment for ischaemic stroke, published in 2013, were neutral but li

234 rrhage and mortality, in patients with acute ischaemic stroke receiving endovascular therapies.

235 cades in high-income countries, incidence of ischaemic stroke reduced significantly by 13% (95% CI 6-

236 l pruritus, trigeminal trophic syndrome, and ischaemic stroke-related itch.

237 Intravenous thrombolysis for ischaemic stroke remains underused worldwide.

238 risis, spontaneous intracranial hypotension, ischaemic stroke, retroclival haematoma, pituitary apopl

239 which have been shown to be associated with ischaemic stroke risk.

240 Patients with ischaemic stroke selected by clinical symptoms and CT be

241 been adopted from experimental and clinical ischaemic stroke studies.

242 Patients can present with headache, ischaemic stroke, subarachnoid haemorrhage, or symptoms

243 In a mouse model of ischaemic stroke, subcellular fractionation studies veri

244 ific rehabilitation therapies and those with ischaemic stroke subtype receiving aspirin in the acute

245 w in which we identified cohort studies with ischaemic stroke subtype-specific follow-up data on deat

246 There is some evidence that recurrent ischaemic stroke subtypes breed true.

247 Among ischaemic stroke subtypes, lacunar strokes, which were o

248 In analysis of ischaemic stroke subtypes, the myeloperoxidase increasin

249 n with primary intracerebral haemorrhage and ischaemic stroke subtypes.

250 It is unclear if risk differs between ischaemic stroke subtypes.

251 34) children were at higher risk of arterial ischaemic stroke than were white children.

252 argest randomised controlled trials in acute ischaemic stroke that compared heparins (unfractionated

253 nt-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple

254 xel-based level, however (and in common with ischaemic stroke), the extent of irreversible tissue dam

255 In patients with ischaemic stroke, the first acute-phase systolic blood p

256 By contrast with findings in ischaemic stroke, the mean first systolic blood pressure

257 ders and Stroke trial, has transformed acute ischaemic stroke therapy.

258 ebral haemorrhage was more likely than after ischaemic stroke to be the highest ever recorded (OR 3.4

259 small vessel disease, in a patient cohort of ischaemic stroke/transient ischaemic attack (TIA) referr

260 es assessing ICH risk in patients with acute ischaemic stroke treated with thrombolysis, in relation

261 By contrast with advances in ischaemic stroke treatment, few evidence-based targeted

262 ecent advances in the gold standard of acute ischaemic stroke treatment, some aspects of which-aspiri

263 ith poor collaterals, in patients with acute ischaemic stroke under EVT.

264 s control given within 6 h of onset of acute ischaemic stroke up to March 30, 2012.

265 aluated 116 individuals within 24 h of acute ischaemic stroke using a battery of oral and written nam

266 ons with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from sev

267 Of the 1141 patients with ischaemic stroke, vascular territory was categorisable i

268 452 participants in the aspirin group had an ischaemic stroke vs 175 of 7326; hazard ratio [HR] 0.42,

269 TIA or minor stroke had a disabling or fatal ischaemic stroke vs 23 of 5726 in the control group, HR

270 The crude incidence of childhood arterial ischaemic stroke was 1.60 per 100 000 per year (95% CI 1

271 e maximum premorbid level whereas that after ischaemic stroke was 5.2 mm Hg lower (p<0.0001).

272 only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for us

273 Alteplase treatment within 6 h after ischaemic stroke was associated with a small, non-signif

274 The effect of aspirin on early recurrent ischaemic stroke was due partly to a substantial reducti

275 The incidence of arterial ischaemic stroke was highest in children aged under 1 ye

276 least one risk factor for childhood arterial ischaemic stroke was identified in 80 (83%) cases.

277 In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of ons

278 control in secondary prevention after TIA or ischaemic stroke, we studied the effects of aspirin on t

279 ean age 60.5 +/- 10.5 years) with first-ever ischaemic strokes, we assessed erectile function after a

280 ed Rankin Scale score 2-4) 6-60 months after ischaemic stroke were implanted with single doses of 2 m

281 years) receiving tPA treatment for confirmed ischaemic stroke were included.

282 tions with a discharge diagnosis of an acute ischaemic stroke were included.

283 s after transient ischaemic attack and minor ischaemic stroke, what factors identify individuals at p

284 ic variants can be detected in patients with ischaemic stroke when compared with controls, all associ

285 ted with intracerebral haemorrhage than with ischaemic stroke, whereas current smoking, diabetes, apo

286 Patients with acute ischaemic stroke who could be treated within 8 h of symp

287 ata from 333 consecutive patients with acute ischaemic stroke who underwent susceptibility-weighted i

288 We enrolled 4947 (99%) of 4992 patients with ischaemic stroke who were admitted to hospitals in Tyrol

289 There was no evidence that patients with ischaemic stroke who were at higher risk of thrombotic e

290 en treated with alteplase for acute arterial ischaemic stroke who were enrolled in the International

291 Patients with ischaemic stroke who were of advanced age, had increased

292 1762 patients with acute ischaemic stroke who were unable to walk unassisted were

293 months) rats treated 24 h following cortical ischaemic stroke with human NT3 delivered using a clinic

294 thrombectomy (MT) in patients who had acute ischaemic stroke with large artery occlusive anterior ci

295 ere eligible for inclusion if they had acute ischaemic stroke with moderate to severe neurological de

296 Early treatment of acute ischaemic stroke with rtPA reduces the risk of longer te

297 Current treatment of ischaemic stroke with thrombolytic therapy is restricted

298 f heart attack, of revascularisation, and of ischaemic stroke, with each 1.0 mmol/L reduction reducin

299 d no effect on risk or severity of recurrent ischaemic stroke within 12 weeks (OR 0.90, 95% CI 0.65-1

300 The best neuroprotectant for acute ischaemic stroke would always be the rapid return of oxy